Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

PCSK9 Inhibitors: From Nature’s Lessons to Clinical Utility

Author(s): Frederick J. Raal*, Robert Chilton, Naresh Ranjith, Virendra Rambiritch, Rory F. Leisegang, Iftikhar O. Ebrahim, Alet van Tonder, Nelusha Shunmoogam, Célia Bouharati, Moji G. Musa, Sumanth Karamchand, Poobalan Naidoo and Dirk J. Blom

Volume 20, Issue 6, 2020

Page: [840 - 854] Pages: 15

DOI: 10.2174/1871530320666200213114138

Price: $65

conference banner
Abstract

Background: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel class of non-statin lipid lowering therapy that reduce LDL-cholesterol by 50 - 60%. PCSK9 inhibitors decrease LDL-cholesterol by preventing intracellular degradation of LDL receptors; subsequently, a greater number of LDL-receptors are available on the cell surface to extract circulating LDL.

Objective: To describe the origins of PCSK9 inhibitors and their current use in clinical practice.

Methods: We performed a narrative review of the PCSK9 inhibitor class of drugs.

Results: Current data indicate that PCSK9 inhibitors effectively reduce LDL-cholesterol and are well tolerated and safe. PCSK9 inhibitors have also been shown to reduce cardiovascular event rates in patients with stable atherosclerotic cardiovascular disease and in patients with a recent (up to one year) acute coronary syndrome. Given the costs, chronicity of the treatment and the potential budget impact, PCSK9 inhibitors are often limited to patients with the highest absolute risk for major adverse cardiovascular events despite optimal treatment with high-intensity statin and ezetimibe.

Conclusion: PCSK9 inhibitors have a favorable safety, efficacy and tolerability profile. Postmarketing safety surveillance and real-world studies are needed to further support the long-term safety profile of this class of medicine.

Keywords: PCSK9 inhibitors, LDL-cholesterol, atherosclerotic cardiovascular disease, major adverse cardiovascular events, acute coronary syndrome, high intensity statin, ezetimibe.

« Previous Next »
Graphical Abstract

[1]
World Health Organization; 2018.Available at:. http://www.who.int/mediacentre/factsheets/fs310/en/ (Accessed on September 1, 2019).
[2]
Yusuf, S.; Hawken, S.; Ounpuu, S. Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J.; Lisheng, L. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet, 2004, 364(9438), 937-952.
[http://dx.doi.org/10.1016/S0140-6736(04)17018-9] [PMID: 15364185]
[3]
Catapano, A.L.; Graham, I.; De Backer, G.; Wiklund, O.; Chapman, M.J.; Drexel, H.; Hoes, A.W.; Jennings, C.S.; Landmesser, U.; Pedersen, T.R.; Reiner, Ž.; Riccardi, G.; Taskinen, M.R.; Tokgozoglu, L.; Verschuren, W.M.M.; Vlachopoulos, C.; Wood, D.A.; Zamorano, J.L.; Cooney, M.T. ESC scientific document group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur. Heart J., 2016, 37(39), 2999-3058.
[http://dx.doi.org/10.1093/eurheartj/ehw272] [PMID: 27567407]
[4]
Danchin, N.; Almahmeed, W.; Al-Rasadi, K.; Azuri, J.; Berrah, A.; Cuneo, C.A.; Karpov, Y.; Kaul, U.; Kayıkçıoğlu, M.; Mitchenko, O.; Ruiz, A.J.; Aguilar Salinas, C.A.; Santos, R.D.; Mercier, F.; Blom, D. ICLPS Investigators. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the international cholesterol management practice study (ICLPS). Eur. J. Prev. Cardiol., 2018, 25(10), 1087-1094.
[http://dx.doi.org/10.1177/2047487318777079] [PMID: 29771156]
[5]
Chiang, C.E.; Ferrières, J.; Gotcheva, N.N.; Raal, F.J.; Shehab, A.; Sung, J.; Henriksson, K.M.; Hermans, M.P. Suboptimal control of lipid levels: Results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHEUS). J. Atheroscler. Thromb., 2016, 23(5), 567-587.
[http://dx.doi.org/10.5551/jat.31179] [PMID: 26632163]
[6]
Gitt, A.K.; Lautsch, D.; Ferrieres, J.; Kastelein, J.; Drexel, H.; Horack, M.; Brudi, P.; Vanneste, B.; Bramlage, P.; Chazelle, F.; Sazonov, V.; Ambegaonkar, B. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis, 2016, 255, 200-209.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.09.004] [PMID: 27667299]
[7]
Banegas, J.R.; López-García, E.; Dallongeville, J.; Guallar, E.; Halcox, J.P.; Borghi, C.; Massó-González, E.L.; Jiménez, F.J.; Perk, J.; Steg, P.G.; De Backer, G.; Rodríguez-Artalejo, F. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur. Heart J., 2011, 32(17), 2143-2152.
[http://dx.doi.org/10.1093/eurheartj/ehr080] [PMID: 21471134]
[8]
Blom, D.J.; Raal, F.; Amod, A.; Naidoo, P.; Lai, Y.E. ICLPS SA study group. Management of low-density lipoprotein cholesterol levels in South Africa: The international cholesterol management practice study (ICLPS). Cardiovasc. J. Afr., 2019, 16(30), 1-9.
[9]
Cariou, B.; Le May, C.; Costet, P. Clinical aspects of PCSK9. Atherosclerosis, 2011, 216(2), 258-265.
[http://dx.doi.org/10.1016/j.atherosclerosis.2011.04.018] [PMID: 21596380]
[10]
Catapano, A.L.; Papadopoulos, N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis, 2013, 228(1), 18-28.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.01.044] [PMID: 23466067]
[11]
Seidah, N.G.; Chrétien, M. Proprotein and prohormone convertases: A family of subtilases generating diverse bioactive polypeptides. Brain Res., 1999, 848(1-2), 45-62.
[http://dx.doi.org/10.1016/S0006-8993(99)01909-5] [PMID: 10701998]
[12]
Benjannet, S.; Rhainds, D.; Essalmani, R.; Mayne, J.; Wickham, L.; Jin, W.; Asselin, M.C.; Hamelin, J.; Varret, M.; Allard, D.; Trillard, M.; Abifadel, M.; Tebon, A.; Attie, A.D.; Rader, D.J.; Boileau, C.; Brissette, L.; Chrétien, M.; Prat, A.; Seidah, N.G. NARC-1/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem., 2004, 279(47), 48865-48875.
[http://dx.doi.org/10.1074/jbc.M409699200] [PMID: 15358785]
[13]
Abifadel, M.; Varret, M.; Rabès, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derré, A.; Villéger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J.M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N.G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003, 34(2), 154-156.
[http://dx.doi.org/10.1038/ng1161] [PMID: 12730697]
[14]
Poirier, S.; Mayer, G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des. Devel. Ther., 2013, 7, 1135-1148.
[PMID: 24115837]
[15]
Hopkins, P.N.; Defesche, J.; Fouchier, S.W.; Bruckert, E.; Luc, G.; Cariou, B.; Sjouke, B.; Leren, T.P.; Harada-Shiba, M.; Mabuchi, H.; Rabès, J.P.; Carrié, A.; van Heyningen, C.; Carreau, V.; Farnier, M.; Teoh, Y.P.; Bourbon, M.; Kawashiri, M.A.; Nohara, A.; Soran, H.; Marais, A.D.; Tada, H.; Abifadel, M.; Boileau, C.; Chanu, B.; Katsuda, S.; Kishimoto, I.; Lambert, G.; Makino, H.; Miyamoto, Y.; Pichelin, M.; Yagi, K.; Yamagishi, M.; Zair, Y.; Mellis, S.; Yancopoulos, G.D.; Stahl, N.; Mendoza, J.; Du, Y.; Hamon, S.; Krempf, M.; Swergold, G.D. characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ Cardiovasc Genet, 2015, 8(6), 823-831.
[http://dx.doi.org/10.1161/CIRCGENETICS.115.001129] [PMID: 26374825]
[16]
Cohen, J.C.; Boerwinkle, E.; Mosley, T.H., Jr; Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med., 2006, 354(12), 1264-1272.
[http://dx.doi.org/10.1056/NEJMoa054013] [PMID: 16554528]
[17]
Desai, N.R.; Sabatine, M.S. PCSK9 inhibition in patients with hypercholesterolemia. Trends Cardiovasc. Med., 2015, 25(7), 567-574.
[http://dx.doi.org/10.1016/j.tcm.2015.01.009] [PMID: 25771732]
[18]
Ridker, P.M.; Amarenco, P.; Brunell, R.; Glynn, R.J.; Jukema, J.W.; Kastelein, J.J.; Koenig, W.; Nissen, S.; Revkin, J.; Santos, R.D.; Schwartz, P.F.; Yunis, C.; Tardif, J.C. Studies of PCSK9 inhibition and the reduction of vascular events (SPIRE) investigators. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the studies of PCSK9 inhibition and the reduction of vascular events (SPIRE) lipid lowering and spire cardiovascular outcomes trials. Am. Heart J., 2016, 178, 135-144.
[http://dx.doi.org/10.1016/j.ahj.2016.05.010] [PMID: 27502861]
[19]
Farnier, M. PCSK9: From discovery to therapeutic applications. Arch. Cardiovasc. Dis., 2014, 107(1), 58-66.
[http://dx.doi.org/10.1016/j.acvd.2013.10.007] [PMID: 24373748]
[20]
Toth, P.P.; Descamps, O.; Genest, J.; Sattar, N.; Preiss, D.; Dent, R.; Djedjos, C.; Wu, Y.; Geller, M.; Uhart, M.; Somaratne, R.; Wasserman, S.M. PROFICIO Investigators. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation, 2017, 135(19), 1819-1831.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025233] [PMID: 28249876]
[21]
Dicembrini, I.; Giannini, S.; Ragghianti, B.; Mannucci, E.; Monami, M. Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J. Endocrinol. Invest., 2019, 42(9), 1029-1039.
[http://dx.doi.org/10.1007/s40618-019-01019-4] [PMID: 30762200]
[22]
Roth, E.M.; McKenney, J.M. ODYSSEY MONO: Effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol., 2015, 11(1), 27-37.
[http://dx.doi.org/10.2217/fca.14.82] [PMID: 25606700]
[23]
Nissen, S.E.; Stroes, E.; Dent-Acosta, R.E.; Rosenson, R.S.; Lehman, S.J.; Sattar, N.; Preiss, D.; Bruckert, E.; Ceška, R.; Lepor, N.; Ballantyne, C.M.; Gouni-Berthold, I.; Elliott, M.; Brennan, D.M.; Wasserman, S.M.; Somaratne, R.; Scott, R.; Stein, E.A. GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. JAMA, 2016, 315(15), 1580-1590.
[http://dx.doi.org/10.1001/jama.2016.3608] [PMID: 27039291]
[24]
Moriarty, P.M.; Thompson, P.D.; Cannon, C.P.; Guyton, J.R.; Bergeron, J.; Zieve, F.J.; Bruckert, E.; Jacobson, T.A.; Kopecky, S.L.; Baccara-Dinet, M.T.; Du, Y.; Pordy, R.; Gipe, D.A. ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol., 2015, 9(6), 758-769.
[http://dx.doi.org/10.1016/j.jacl.2015.08.006] [PMID: 26687696]
[25]
Schwartz, G.G.; Steg, P.G.; Szarek, M.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Edelberg, J.M.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; Jukema, J.W.; Lecorps, G.; Mahaffey, K.W.; Moryusef, A.; Pordy, R.; Quintero, K.; Roe, M.T.; Sasiela, W.J.; Tamby, J.F.; Tricoci, P.; White, H.D.; Zeiher, A.M. ODYSSEY OUTCOMES committees and investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med., 2018, 379(22), 2097-2107.
[http://dx.doi.org/10.1056/NEJMoa1801174] [PMID: 30403574]]
[26]
Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; Sever, P.S.; Pedersen, T.R. FOURIER steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med., 2017, 376(18), 1713-1722.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[27]
Bays, H.; Gaudet, D.; Weiss, R.; Ruiz, J.L.; Watts, G.F.; Gouni-Berthold, I.; Robinson, J.; Zhao, J.; Hanotin, C.; Donahue, S. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J. Clin. Endocrinol. Metab., 2015, 100(8), 3140-3148.
[http://dx.doi.org/10.1210/jc.2015-1520] [PMID: 26030325]
[28]
Farnier, M.; Jones, P.; Severance, R.; Averna, M.; Steinhagen-Thiessen, E.; Colhoun, H.M.; Du, Y.; Hanotin, C.; Donahue, S. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis, 2016, 244, 138-146.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.11.010] [PMID: 26638010]
[29]
Nozue, T. Lipid lowering therapy and circulating PCSK9 concentration. J. Atheroscler. Thromb., 2017, 24(9), 895-907.
[http://dx.doi.org/10.5551/jat.RV17012] [PMID: 28804094]
[30]
Kastelein, J.J.; Ginsberg, H.N.; Langslet, G.; Hovingh, G.K.; Ceska, R.; Dufour, R.; Blom, D.; Civeira, F.; Krempf, M.; Lorenzato, C.; Zhao, J.; Pordy, R.; Baccara-Dinet, M.T.; Gipe, D.A.; Geiger, M.J.; Farnier, M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J., 2015, 36(43), 2996-3003.
[http://dx.doi.org/10.1093/eurheartj/ehv370] [PMID: 26330422]
[31]
Raal, F.J.; Stein, E.A.; Dufour, R.; Turner, T.; Civeira, F.; Burgess, L.; Langslet, G.; Scott, R.; Olsson, A.G.; Sullivan, D.; Hovingh, G.K.; Cariou, B.; Gouni-Berthold, I.; Somaratne, R.; Bridges, I.; Scott, R.; Wasserman, S.M.; Gaudet, D. RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet, 2015, 385(9965), 331-340.
[http://dx.doi.org/10.1016/S0140-6736(14)61399-4] [PMID: 25282519]
[32]
Raal, F.J.; Honarpour, N.; Blom, D.J.; Hovingh, G.K.; Xu, F.; Scott, R.; Wasserman, S.M.; Stein, E.A. TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet, 2015, 385(9965), 341-350.
[http://dx.doi.org/10.1016/S0140-6736(14)61374-X] [PMID: 25282520]
[33]
Robinson, J.G.; Farnier, M.; Krempf, M.; Bergeron, J.; Luc, G.; Averna, M.; Stroes, E.S.; Langslet, G.; Raal, F.J.; El Shahawy, M.; Koren, M.J.; Lepor, N.E.; Lorenzato, C.; Pordy, R.; Chaudhari, U.; Kastelein, J.J. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med., 2015, 372(16), 1489-1499.
[http://dx.doi.org/10.1056/NEJMoa1501031] [PMID: 25773378]
[34]
Ginsberg, H.N.; Rader, D.J.; Raal, F.J.; Guyton, J.R.; Baccara-Dinet, M.T.; Lorenzato, C.; Pordy, R.; Stroes, E. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc. Drugs Ther., 2016, 30(5), 473-483.
[http://dx.doi.org/10.1007/s10557-016-6685-y] [PMID: 27618825]
[35]
Kereiakes, D.J.; Robinson, J.G.; Cannon, C.P.; Lorenzato, C.; Pordy, R.; Chaudhari, U.; Colhoun, H.M. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am. Heart J., 2015, 169(6), 906-915.e13.
[http://dx.doi.org/10.1016/j.ahj.2015.03.004] [PMID: 26027630]
[36]
El Shahawy, M.; Cannon, C.P.; Blom, D.J.; McKenney, J.M.; Cariou, B.; Lecorps, G.; Pordy, R.; Chaudhari, U.; Colhoun, H.M. Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II). Am. J. Cardiol., 2017, 120(6), 931-939.
[http://dx.doi.org/10.1016/j.amjcard.2017.06.023] [PMID: 28750828]
[37]
Koren, M.J.; Lundqvist, P.; Bolognese, M.; Neutel, J.M.; Monsalvo, M.L.; Yang, J.; Kim, J.B.; Scott, R.; Wasserman, S.M.; Bays, H. MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J. Am. Coll. Cardiol., 2014, 63(23), 2531-2540.
[http://dx.doi.org/10.1016/j.jacc.2014.03.018] [PMID: 24691094]
[38]
Robinson, J.G.; Nedergaard, B.S.; Rogers, W.J.; Fialkow, J.; Neutel, J.M.; Ramstad, D.; Somaratne, R.; Legg, J.C.; Nelson, P.; Scott, R.; Wasserman, S.M.; Weiss, R. LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA, 2014, 311(18), 1870-1882.
[http://dx.doi.org/10.1001/jama.2014.4030] [PMID: 24825642]
[39]
Stroes, E.; Colquhoun, D.; Sullivan, D.; Civeira, F.; Rosenson, R.S.; Watts, G.F.; Bruckert, E.; Cho, L.; Dent, R.; Knusel, B.; Xue, A.; Scott, R.; Wasserman, S.M.; Rocco, M. GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol., 2014, 63(23), 2541-2548.
[http://dx.doi.org/10.1016/j.jacc.2014.03.019] [PMID: 24694531]
[40]
Blom, D.J.; Hala, T.; Bolognese, M.; Lillestol, M.J.; Toth, P.D.; Burgess, L.; Ceska, R.; Roth, E.; Koren, M.J.; Ballantyne, C.M.; Monsalvo, M.L.; Tsirtsonis, K.; Kim, J.B.; Scott, R.; Wasserman, S.M.; Stein, E.A. DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med., 2014, 370(19), 1809-1819.
[http://dx.doi.org/10.1056/NEJMoa1316222] [PMID: 24678979]
[41]
Ridker, P.M.; Revkin, J.; Amarenco, P.; Brunell, R.; Curto, M.; Civeira, F.; Flather, M.; Glynn, R.J.; Gregoire, J.; Jukema, J.W.; Karpov, Y.; Kastelein, J.J.P.; Koenig, W.; Lorenzatti, A.; Manga, P.; Masiukiewicz, U.; Miller, M.; Mosterd, A.; Murin, J.; Nicolau, J.C.; Nissen, S.; Ponikowski, P.; Santos, R.D.; Schwartz, P.F.; Soran, H.; White, H.; Wright, R.S.; Vrablik, M.; Yunis, C.; Shear, C.L.; Tardif, J.C. SPIRE cardiovascular outcome investigators. cardiovascular efficacy and safety of bococizumab in high-risk patients. N. Engl. J. Med., 2017, 376(16), 1527-1539.
[http://dx.doi.org/10.1056/NEJMoa1701488] [PMID: 28304242]
[42]
Ridker, P.M.; Tardif, J-C.; Amarenco, P.; Duggan, W.; Glynn, R.J.; Jukema, J.W.; Kastelein, J.J.P.; Kim, A.M.; Koenig, W.; Nissen, S.; Revkin, J.; Rose, L.M.; Santos, R.D.; Schwartz, P.F.; Shear, C.L.; Yunis, C. SPIRE investigators. lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Engl. J. Med., 2017, 376(16), 1517-1526.
[http://dx.doi.org/10.1056/NEJMoa1614062] [PMID: 28304227]
[43]
Ference, B.A.; Cannon, C.P.; Landmesser, U.; Lüscher, T.F.; Catapano, A.L.; Ray, K.K. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: An analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur. Heart J., 2018, 39(27), 2540-2545.
[http://dx.doi.org/10.1093/eurheartj/ehx450] [PMID: 29020411]
[44]
Bueno, H.; Martín Asenjo, R. Long-term cardiovascular risk after acute coronary syndrome, an ongoing challenge. Rev. Esp. Cardiol. (Engl. Ed.), 2016, 69(1), 1-2.
[http://dx.doi.org/10.1016/j.rec.2015.08.020] [PMID: 26613869]
[45]
Schwartz, G.G.; Bessac, L.; Berdan, L.G.; Bhatt, D.L.; Bittner, V.; Diaz, R.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; Jukema, J.W.; Mahaffey, K.W.; Moryusef, A.; Pordy, R.; Roe, M.T.; Rorick, T.; Sasiela, W.J.; Shirodaria, C.; Szarek, M.; Tamby, J.F.; Tricoci, P.; White, H.; Zeiher, A.; Steg, P.G. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY outcomes trial. Am. Heart J., 2014, 168(5), 682-689.
[http://dx.doi.org/10.1016/j.ahj.2014.07.028] [PMID: 25440796]
[46]
Silverman, M.G.; Ference, B.A. Im, K.; Wiviott, S.D.; Giugliano, R.P.; Grundy, S.M.; Braunwald, E.; Sabatine, M.S. Im, K.; Wiviott, S.D.; Giugliano, R.P.; Grundy, S.M.; Braunwald, E.; Sabatine, M.S.; Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA, 2016, 316(12), 1289-1297.
[http://dx.doi.org/10.1001/jama.2016.13985] [PMID: 27673306]
[47]
Jukema, J.W.; Szarek, M.; Zijlstra, L.E.; de Silva, H.A.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Edelberg, J.M.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; Karpov, Y.; Moryusef, A.; Pordy, R.; Prieto, J.C.; Roe, M.T.; White, H.D.; Zeiher, A.M.; Schwartz, G.G.; Steg, P.G. ODYSSEY OUTCOMES committees and investigators Patients with recent acute coronary syndrome and polyvascular disease derive large absolute benefit from alirocumab: ODYSSEY OUTCOMES trial. J. Am. Coll. Cardiol,, 2019.. S0735-1097(19)33921-X.
[48]
Sabatine, M.S.; De Ferrari, G.M.; Giugliano, R.P.; Huber, K.; Lewis, B.S.; Ferreira, J.; Kuder, J.F.; Murphy, S.A.; Wiviott, S.D.; Kurtz, C.E.; Honarpour, N.; Keech, A.C.; Sever, P.S.; Pedersen, T.R. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. Circulation, 2018, 138(8), 756-766.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034309] [PMID: 29626068]
[49]
Bonaca, M.P.; Nault, P.; Giugliano, R.P.; Keech, A.C.; Pineda, A.L.; Kanevsky, E.; Kuder, J.; Murphy, S.A.; Jukema, J.W.; Lewis, B.S.; Tokgozoglu, L.; Somaratne, R.; Sever, P.S.; Pedersen, T.R.; Sabatine, M.S. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation, 2018, 137(4), 338-350.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032235] [PMID: 29133605]
[50]
Sabatine, M.S.; Leiter, L.A.; Wiviott, S.D.; Giugliano, R.P.; Deedwania, P.; De Ferrari, G.M.; Murphy, S.A.; Kuder, J.F.; Gouni Berthold, I.; Lewis, B.S.; Handelsman, Y.; Pineda, A.L.; Honarpour, N.; Keech, A.C.; Sever, P.S.; Pedersen, T.R. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol., 2017, 5(12), 941-950.
[http://dx.doi.org/10.1016/S2213-8587(17)30313-3] [PMID: 28927706]
[51]
Leiter, L.A.; Tinahones, F.J.; Karalis, D.G.; Bujas-Bobanovic, M.; Letierce, A.; Mandel, J.; Samuel, R.; Jones, P.H. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet. Med., 2018, 35(12), 1742-1751.
[http://dx.doi.org/10.1111/dme.13817] [PMID: 30183102]
[52]
Jones, P.H.; Bays, H.E.; Chaudhari, U.; Pordy, R.; Lorenzato, C.; Miller, K.; Robinson, J.G. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. Am. J. Cardiol., 2016, 118(12), 1805-1811.
[http://dx.doi.org/10.1016/j.amjcard.2016.08.072] [PMID: 27729106]
[53]
Chen, X.; Hui, L.; Geiger, J.D. Role of LDL cholesterol and endolysosomes in amyloidogenesis and Alzheimer’s disease. J. Neurol. Neurophysiol., 2014, 5(5), 236.
[http://dx.doi.org/10.4172/2155-9562.1000236] [PMID: 26413387]
[54]
Giugliano, R.P.; Pedersen, T.R.; Park, J.G.; De Ferrari, G.M.; Gaciong, Z.A.; Ceska, R.; Toth, K.; Gouni-Berthold, I.; Lopez-Miranda, J.; Schiele, F.; Mach, F.; Ott, B.R.; Kanevsky, E.; Pineda, A.L.; Somaratne, R.; Wasserman, S.M.; Keech, A.C.; Sever, P.S.; Sabatine, M.S. FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. Lancet, 2017, 390(10106), 1962-1971.
[http://dx.doi.org/10.1016/S0140-6736(17)32290-0] [PMID: 28859947]
[55]
Khan, A.R.; Bavishi, C.; Riaz, H.; Farid, T.A.; Khan, S.; Atlas, M.; Hirsch, G.; Ikram, S.; Bolli, R. Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors. Circ. Cardiovasc. Qual. Outcomes, 2017, 10(1),e003153.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.116.003153] [PMID: 28073851]
[56]
Lipinski, M.J.; Benedetto, U.; Escarcega, R.O.; Biondi-Zoccai, G.; Lhermusier, T.; Baker, N.C.; Torguson, R.; Brewer, H.B., Jr; Waksman, R. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis. Eur. Heart J., 2016, 37(6), 536-545.
[http://dx.doi.org/10.1093/eurheartj/ehv563] [PMID: 26578202]
[57]
Koren, M.J.; Giugliano, R.P.; Raal, F.J.; Sullivan, D.; Bolognese, M.; Langslet, G.; Civeira, F.; Somaratne, R.; Nelson, P.; Liu, T.; Scott, R.; Wasserman, S.M.; Sabatine, M.S. OSLER Investigators. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation, 2014, 129(2), 234-243.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007012] [PMID: 24255061]
[58]
Giugliano, R.P.; Mach, F.; Zavitz, K.; Kurtz, C. Im, K.; Kanevsky, E.; Schneider, J.; Wang, H.; Keech, A.; Pedersen, T.R.; Sabatine, M.S.; Sever, P.S.; Robinson, J.G.; Honarpour, N.; Wasserman, S.M.; Ott, B.R. EBBINGHAUS Investigators. Cognitive Function in a Randomized Trial of Evolocumab. N. Engl. J. Med., 2017, 377(7), 633-643.
[http://dx.doi.org/10.1056/NEJMoa1701131] [PMID: 28813214]
[59]
National Institutes of Health (NIH)). 2020. Available at:. https://clinicaltrials.gov/ct2/show/NCT02957682 (Accessed on September 1, 2019).
[60]
Hsia, J.; MacFadyen, J.G.; Monyak, J.; Ridker, P.M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin). J. Am. Coll. Cardiol., 2011, 57(16), 1666-1675.
[http://dx.doi.org/10.1016/j.jacc.2010.09.082] [PMID: 21492764]
[61]
Giugliano, R.P.; Wiviott, S.D.; Blazing, M.A.; De Ferrari, G.M.; Park, J.G.; Murphy, S.A.; White, J.A.; Tershakovec, A.M.; Cannon, C.P.; Braunwald, E. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: A prespecified analysis of the IMPROVE-IT Trial. JAMA Cardiol., 2017, 2(5), 547-555.
[http://dx.doi.org/10.1001/jamacardio.2017.0083] [PMID: 28291866]
[62]
Olsson, A.G.; Angelin, B.; Assmann, G.; Binder, C.J.; Björkhem, I.; Cedazo-Minguez, A.; Cohen, J.; von Eckardstein, A.; Farinaro, E.; Müller-Wieland, D.; Parhofer, K.G.; Parini, P.; Rosenson, R.S.; Starup-Linde, J.; Tikkanen, M.J.; Yvan-Charvet, L. Can LDL cholesterol be too low? Possible risks of extremely low levels. J. Intern. Med., 2017, 281(6), 534-553.
[http://dx.doi.org/10.1111/joim.12614] [PMID: 28295777]
[63]
Robinson, J.G.; Rosenson, R.S.; Farnier, M.; Chaudhari, U.; Sasiela, W.J.; Merlet, L.; Miller, K.; Kastelein, J.J. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J. Am. Coll. Cardiol., 2017, 69(5), 471-482.
[http://dx.doi.org/10.1016/j.jacc.2016.11.037] [PMID: 28153102]
[64]
Blom, D.J.; Djedjos, C.S.; Monsalvo, M.L.; Bridges, I.; Wasserman, S.M.; Scott, R.; Roth, E. Effects of evolocumab on vitamin e and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ. Res., 2015, 117(8), 731-741.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.307071] [PMID: 26228031]
[65]
Hess, G.P.; Natarajan, P.; Faridi, K.F.; Fievitz, A.; Valsdottir, L.; Yeh, R.W. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: Payer approvals and rejections, and patient characteristics for successful prescribing. Circulation, 2017, 136(23), 2210-2219.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028430] [PMID: 29084735]
[66]
Draft Report, I.C.E.R. 2017.Available at:, https://icer-review.org/announcements/pcsk9-draft-report-release/(Accessed on September 1, 2019)..
[67]
Institute for Clinical and Economic Review (ICER). 2017.https://icer-review.org/wp-content/uploads/2017/06/ICER_PCSK9_NEU_091117.pdf
[68]
Institute for Clinical and Economic Review (ICER). Alirocumab for treatment of high cholesterol: Effectiveness and value.Available at:, https://icer-review.org/wp-content/uploads/2019/02/ICER_Alirocumab_Final_NEU_021519.pdf(Accessed on September 1, 2019)..
[69]
Korman, M.J.; Retterstøl, K.; Kristiansen, I.S.; Wisløff, T. Are PCSK9 Inhibitors Cost Effective? Pharmacoeconomics, 2018, 36(9), 1031-1041.
[http://dx.doi.org/10.1007/s40273-018-0671-0] [PMID: 29777433]
[70]
Fonarow, G.C.; Keech, A.C.; Pedersen, T.R.; Giugliano, R.P.; Sever, P.S.; Lindgren, P.; van Hout, B.; Villa, G.; Qian, Y.; Somaratne, R.; Sabatine, M.S. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol., 2017, 2(10), 1069-1078.
[http://dx.doi.org/10.1001/jamacardio.2017.2762] [PMID: 28832867]
[71]
Kazi, D.S.; Penko, J.; Coxson, P.G.; Moran, A.E.; Ollendorf, D.A.; Tice, J.A.; Bibbins-Domingo, K. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA, 2017, 318(8), 748-750.
[http://dx.doi.org/10.1001/jama.2017.9924] [PMID: 28829863]
[72]
Baum, S.J.; Cannon, C.P. PCSK9 inhibitor valuation: A science-based review of the two recent models. Clin. Cardiol., 2018, 41(4), 544-550.
[http://dx.doi.org/10.1002/clc.22924] [PMID: 29512936]
[73]
Landmesser, U.; Chapman, M.J.; Stock, J.K.; Amarenco, P.; Belch, J.J.F.; Borén, J.; Farnier, M.; Ference, B.A.; Gielen, S.; Graham, I.; Grobbee, D.E.; Hovingh, G.K.; Lüscher, T.F.; Piepoli, M.F.; Ray, K.K.; Stroes, E.S.; Wiklund, O.; Windecker, S.; Zamorano, J.L.; Pinto, F.; Tokgözoglu, L.; Bax, J.J.; Catapano, A.L. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur. Heart J., 2018, 39(14), 1131-1143.
[http://dx.doi.org/10.1093/eurheartj/ehx549] [PMID: 29045644]
[74]
Stam-Slob, M.C.; van der Graaf, Y.; de Boer, A.; Greving, J.P.; Visseren, F.L.J. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. Int. J. Cardiol., 2018, 253, 148-154.
[http://dx.doi.org/10.1016/j.ijcard.2017.10.080] [PMID: 29306457]
[75]
Nordestgaard, B.G.; Chapman, M.J.; Humphries, S.E.; Ginsberg, H.N.; Masana, L.; Descamps, O.S.; Wiklund, O.; Hegele, R.A.; Raal, F.J.; Defesche, J.C.; Wiegman, A.; Santos, R.D.; Watts, G.F.; Parhofer, K.G.; Hovingh, G.K.; Kovanen, P.T.; Boileau, C.; Averna, M.; Borén, J.; Bruckert, E.; Catapano, A.L.; Kuivenhoven, J.A.; Pajukanta, P.; Ray, K.; Stalenhoef, A.F.; Stroes, E.; Taskinen, M.R.; Tybjærg-Hansen, A. European atherosclerosis society consensus panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur. Heart J., 2013, 34(45), 3478-90a.
[http://dx.doi.org/10.1093/eurheartj/eht273] [PMID: 23956253]
[76]
Masana, L.; Plana, N.; Pérez-Calahorra, S.; Ibarretxe, D.; Lamiquiz Moneo, I.; Pedro-Botet, J.; Suárez-Tembra, M.; Valdivielso, P.; Ortega, E.; Civeira, F. Dyslipidemia registry of the Spanish arteriosclerosis society. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition? Atherosclerosis, 2017, 262, 107-112.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.05.013] [PMID: 28531826]
[77]
Cuchel, M.; Bruckert, E.; Ginsberg, H.N.; Raal, F.J.; Santos, R.D.; Hegele, R.A.; Kuivenhoven, J.A.; Nordestgaard, B.G.; Descamps, O.S.; Steinhagen-Thiessen, E.; Tybjærg-Hansen, A.; Watts, G.F.; Averna, M.; Boileau, C.; Borén, J.; Catapano, A.L.; Defesche, J.C.; Hovingh, G.K.; Humphries, S.E.; Kovanen, P.T.; Masana, L.; Pajukanta, P.; Parhofer, K.G.; Ray, K.K.; Stalenhoef, A.F.; Stroes, E.; Taskinen, M.R.; Wiegman, A.; Wiklund, O.; Chapman, M.J. European atherosclerosis society consensus panel on familial hypercholesterolaemia. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European atherosclerosis society. Eur. Heart J., 2014, 35(32), 2146-2157.
[http://dx.doi.org/10.1093/eurheartj/ehu274] [PMID: 25053660]
[78]
Smyth, N.; Ramsay, M.; Raal, F.J. Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa. Curr. Opin. Lipidol., 2018, 29(2), 72-79.
[http://dx.doi.org/10.1097/MOL.0000000000000488] [PMID: 29369830]

Rights & Permissions Print Cite
Article Metrics
25
1
© 2024 Bentham Science Publishers | Privacy Policy